Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics

• Material Type: 記事
• Title: Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics
• Author Heading: Todo Kenichi; Ikeguchi Ryotaro; Shimizu Yuko
• Publication Date: 2026
• Publication Date (W3CDTF): 2026
• Periodical title: Internal Medicine
• No. or year of volume/issue: advpub 0
• Volume: advpub
• Issue: 0
• Publication date of volume/issue (W3CDTF): 2026
• ISSN (Periodical Title): 09182918
• Publication (Periodical Title): The Japanese Society of Internal Medicine
• Text Language Code: en
• Subject Heading: biologics; glucocorticoid; neuromyelitis optica spectrum disorder; aquaporin-4; monoclonal antibody therapy
• Target Audience: 一般
• Standard No. (Other): PMID : 41730623
• DOI: 10.2169/internalmedicine.6772-25; https://doi.org/10.2169/internalmedicine.6772-25
• Related Material (URI): https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_6772-25/_pdf
• Is Version Of: 1
• References: Neuromyelitis optica: Passive transfer to rats by human immunoglobulin; https://cir.nii.ac.jp/crid/1360001114218570752; Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro; https://cir.nii.ac.jp/crid/1360002219072390272; CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse; https://cir.nii.ac.jp/crid/1360004236094004608; Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica; https://cir.nii.ac.jp/crid/1360004237536633344; Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy; https://cir.nii.ac.jp/crid/1360009142459832320; Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder; https://cir.nii.ac.jp/crid/1360020700265730048; Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey; https://cir.nii.ac.jp/crid/1360023717932914176; Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD); https://cir.nii.ac.jp/crid/1360023718869738752; Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders; https://cir.nii.ac.jp/crid/1360026064895280640; A comparative study on clinico-radiological profile, treatment responses and outcomes of double seronegative NMOSD compared to AQP4-IgG positive NMOSD, and MOGAD; https://cir.nii.ac.jp/crid/1360026064895281408; Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report; https://cir.nii.ac.jp/crid/1360026064896194560; AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?; https://cir.nii.ac.jp/crid/1360026064904395520; Eculizumab use throughout pregnancy in two patients with aquaporin‐4‐positive neuromyelitis optica spectrum disorder; https://cir.nii.ac.jp/crid/1360026067399282816; Intravenous immunoglobulin as the rescue treatment in NMOSD patients; https://cir.nii.ac.jp/crid/1360026067442222464; Satralizumab treatment in neuromyelitis optica spectrum disorder: effects on relapse, pain, and other medications used: a retrospective chart review; https://cir.nii.ac.jp/crid/1360026068005728384; Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6; https://cir.nii.ac.jp/crid/1360283693894662400; Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature; https://cir.nii.ac.jp/crid/1360285707039244928; CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications; https://cir.nii.ac.jp/crid/1360285711070237056; Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder; https://cir.nii.ac.jp/crid/1360286993686614656; Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis; https://cir.nii.ac.jp/crid/1360292619054938496; CNS Aquaporin‐4‐specific B cells connect with multiple B‐cell compartments in neuromyelitis optica spectrum disorder; https://cir.nii.ac.jp/crid/1360294646973939968; Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis; https://cir.nii.ac.jp/crid/1360306913637569536; Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica; https://cir.nii.ac.jp/crid/1360307541012498432; Rituximab during pregnancy in neuromyelitis optica: A case report; https://cir.nii.ac.jp/crid/1360307541176779520; Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study; https://cir.nii.ac.jp/crid/1360307542404971904; International consensus diagnostic criteria for neuromyelitis optica spectrum disorders; https://cir.nii.ac.jp/crid/1360565169025925888; Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder; https://cir.nii.ac.jp/crid/1360568468663323136; Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial; https://cir.nii.ac.jp/crid/1360572092858758784; IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel; https://cir.nii.ac.jp/crid/1360574094503283712; Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica; https://cir.nii.ac.jp/crid/1360574094763614976; New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD; https://cir.nii.ac.jp/crid/1360576118781847040; Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity; https://cir.nii.ac.jp/crid/1360576121463047168; Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica; https://cir.nii.ac.jp/crid/1360576226650889216; Melanoma Cell Adhesion Molecule Expressing Helper T Cells in CNS Inflammatory Demyelinating Diseases; https://cir.nii.ac.jp/crid/1360584343249170176; AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder; https://cir.nii.ac.jp/crid/1360584345107114880; Neuromyelitis Optica Spectrum Disorder; https://cir.nii.ac.jp/crid/1360588389342068096; CD21lo B-cell subsets are recruited to the central nervous system in acute neuromyelitis optica; https://cir.nii.ac.jp/crid/1360589016531327488; Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder; https://cir.nii.ac.jp/crid/1360589017351398272; Double-negative neuromyelitis optica spectrum disorder; https://cir.nii.ac.jp/crid/1360589017357166720; Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD; https://cir.nii.ac.jp/crid/1360589017960251904; Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica; https://cir.nii.ac.jp/crid/1360846642061385344; Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review; https://cir.nii.ac.jp/crid/1360848656450657920; Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder; https://cir.nii.ac.jp/crid/1360861715100997120; Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder; https://cir.nii.ac.jp/crid/1360868449490125056; Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report; https://cir.nii.ac.jp/crid/1360868450164326272; The real-world impact of biologics for NMOSD: A retrospective single-center study compared with natural course and conventional treatments in Japanese; https://cir.nii.ac.jp/crid/1360869855573658880; Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody; https://cir.nii.ac.jp/crid/1360869859059832576; Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies; https://cir.nii.ac.jp/crid/1360870489461342336; Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: A case report; https://cir.nii.ac.jp/crid/1360870489826616192; Eculizumab Use in Neuromyelitis Optica Spectrum Disorders; https://cir.nii.ac.jp/crid/1360870491509541120; Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD; https://cir.nii.ac.jp/crid/1360870492324912896; Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease; https://cir.nii.ac.jp/crid/1360870492324914048; Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis; https://cir.nii.ac.jp/crid/1360870492325024512; The real-world experience of biologics for neuromyelitis optica spectrum disorders as first-line and switched therapy; https://cir.nii.ac.jp/crid/1360870492325600896; Post marketing real-world experience of ravulizumab in NMOSD; https://cir.nii.ac.jp/crid/1360870492325716096; Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy; https://cir.nii.ac.jp/crid/1360870492401411456; Progress in the management of pregnancy in patients with neuromyelitis optica spectrum disorder; https://cir.nii.ac.jp/crid/1360870492936097920; Aquaporin 4 and neuromyelitis optica; https://cir.nii.ac.jp/crid/1361137043988373120; Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial; https://cir.nii.ac.jp/crid/1361412892426168192; Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology; https://cir.nii.ac.jp/crid/1361418519424622848; Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice; https://cir.nii.ac.jp/crid/1361418519443624320; A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis; https://cir.nii.ac.jp/crid/1361418520398858752; An open label study of the effects of rituximab in neuromyelitis optica; https://cir.nii.ac.jp/crid/1361699995540526208; Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence; https://cir.nii.ac.jp/crid/1361981468729909376; B lymphocytes in neuromyelitis optica; https://cir.nii.ac.jp/crid/1362262945406793216; Aquaporin 4‐specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize <i>Clostridium</i> ABC transporter; https://cir.nii.ac.jp/crid/1362544419986583936; Immunology of neuromyelitis optica: a T cell–B cell collaboration; https://cir.nii.ac.jp/crid/1363670319181792512; IL-17 and Th17 Cells; https://cir.nii.ac.jp/crid/1363951794608098816; Safe Childbirth in a Patient with Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab; https://cir.nii.ac.jp/crid/1390589054383146624; Serious Bacterial Infections Associated with Eculizumab: A Pharmacovigilance Study; https://cir.nii.ac.jp/crid/1390862776828019072; Loss of aquaporin 4 in lesion of neuromyelitis optica: distinction from multiple sclerosis; https://cir.nii.ac.jp/crid/1573387449792686592
• Data Provider (Database): 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• Original Data Provider (Database): Japan Link Center; https://japanlinkcenter.org/top; Crossref; https://www.crossref.org; PubMed; https://pubmed.ncbi.nlm.nih.gov

• Summary, etc.: <p>Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system that affects the optic nerve and...